ArticleFrontiers in public health2026
Initial insights into the relationship between symptomatic COVID-19 disease and specific clinical and blood parameters in patients with alcohol use disorder.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with alcohol use disorder (AUD) are at higher risk for long-term Coronavirus Disease 2019 (COVID-19) related consequences, due to bidirectional relationship and shared biological pathways between chronic alcohol use and COVID-19 disease. However, they are significantly underrepresented in the literature examining adverse outcomes associated with COVID-19 disease. Objective: Therefore, we comprehensively examined the initial group differences between AUD patients who experienced symptomatic COVID-19 disease and AUD patients without a history of COVID-19 disease. We investigated differences between COVID-19 and non-COVID-19 groups in AUD severity (alcohol use, alcohol craving), cognitive functions (assessed by the Montreal Cognitive Assessment), and basic blood parameters. Methods: This pilot study was conducted in two study points 6 months apart. Participants were 32 COVID-19 AUD patients and 31 non-COVID-19 AUD patients, who met rigorous inclusion and exclusion criteria. Sociodemographic questionnaire, COVID-19 interview and validated measurement instruments (5.0.0. Mini International Neuropsychiatric Interview, M.I.N.I.; Penn Alcohol Craving Scale, PACS; Alcohol Use Disorders Identification Test, AUDIT; Montreal Cognitive Assessment, MoCA; Clinical Institute Withdrawal Assessment for Alcohol Scale, Revised, CIWA-Ar) were assessed. Also, blood parameters were measured: erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) as inflammatory; alanine transaminase (ALT), aspartate transaminase (AST) and gamma-glutamyl transferase (GGT) as biochemical; total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides (TG) as lipid parameters. Results: In the COVID-19 group, 93.7 % of participants had a mild form of the disease. There was significant difference between the two groups in cognitive functions which improved in the non-COVID-19 group, whereas they remained unchanged in the COVID-19 group [ Conclusions: Cognitive functions and blood parameters require long-term follow-up in COVID-19 AUD patients. Better clinical and blood outcomes in non-relapse group support the overall benefits of reduction in alcohol use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.